User login
Key clinical point: In patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) treated with pertuzumab, trastuzumab, and docetaxel, rash during treatment and diarrhea after docetaxel discontinuation are predictors of survival outcomes.
Major finding: Development of rash during docetaxel administration predicted progression-free survival (PFS; adjusted hazard ratio [aHR], 0.71; P = .006) and overall survival (OS; aHR, 0.66; P = .01). Development of rash after docetaxel interruption also predicted PFS (aHR, 0.55; P = .002) and OS (aHR, 0.52; P = .018). Diarrhea was prognostic only for PFS (aHR, 0.65; P = .011) after docetaxel discontinuation.
Study details: The data come from a retrospective analysis of CLEOPATRA trial involving 777 patients with de novo or recurrent advanced HER2-positive MBC treated with docetaxel plus trastuzumab with or without pertuzumab.
Disclosures: No specific funding source was identified. Some authors reported receiving travel grants, consultation fees, and honoraria from various pharmaceutical companies.
Source: Ferreira AR et al. Eur J Cancer. 2020 Dec 31. doi: 10.1016/j.ejca.2020.11.023.
Key clinical point: In patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) treated with pertuzumab, trastuzumab, and docetaxel, rash during treatment and diarrhea after docetaxel discontinuation are predictors of survival outcomes.
Major finding: Development of rash during docetaxel administration predicted progression-free survival (PFS; adjusted hazard ratio [aHR], 0.71; P = .006) and overall survival (OS; aHR, 0.66; P = .01). Development of rash after docetaxel interruption also predicted PFS (aHR, 0.55; P = .002) and OS (aHR, 0.52; P = .018). Diarrhea was prognostic only for PFS (aHR, 0.65; P = .011) after docetaxel discontinuation.
Study details: The data come from a retrospective analysis of CLEOPATRA trial involving 777 patients with de novo or recurrent advanced HER2-positive MBC treated with docetaxel plus trastuzumab with or without pertuzumab.
Disclosures: No specific funding source was identified. Some authors reported receiving travel grants, consultation fees, and honoraria from various pharmaceutical companies.
Source: Ferreira AR et al. Eur J Cancer. 2020 Dec 31. doi: 10.1016/j.ejca.2020.11.023.
Key clinical point: In patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) treated with pertuzumab, trastuzumab, and docetaxel, rash during treatment and diarrhea after docetaxel discontinuation are predictors of survival outcomes.
Major finding: Development of rash during docetaxel administration predicted progression-free survival (PFS; adjusted hazard ratio [aHR], 0.71; P = .006) and overall survival (OS; aHR, 0.66; P = .01). Development of rash after docetaxel interruption also predicted PFS (aHR, 0.55; P = .002) and OS (aHR, 0.52; P = .018). Diarrhea was prognostic only for PFS (aHR, 0.65; P = .011) after docetaxel discontinuation.
Study details: The data come from a retrospective analysis of CLEOPATRA trial involving 777 patients with de novo or recurrent advanced HER2-positive MBC treated with docetaxel plus trastuzumab with or without pertuzumab.
Disclosures: No specific funding source was identified. Some authors reported receiving travel grants, consultation fees, and honoraria from various pharmaceutical companies.
Source: Ferreira AR et al. Eur J Cancer. 2020 Dec 31. doi: 10.1016/j.ejca.2020.11.023.